服务平台拥有丰富的技术服务经验，一流的仪器设备，先进的检测手段和严格的质量控制体系，力求为全球药物研发机构提供优质高效的技术服务
背景介绍 PCSK9 is a crucial player in the regulation of plasma cholesterol homeostasis. It binds to the ectodomain of hepatic low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation. PCSK9 acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. The D374T mutation results in higher affinity of PCSK9 for LDLR. 产品介绍 Human proprotein convertase subtilisin/kexin type 9 (PCSK9), also known as FH3, HCHOLA3, and PC9, GenBank Accession No. NM_174936, a.a. 31- 692(end), with C-terminal His- and Avi-tags and a D374T mutation, MW=73.8 kDa, expressed in an HEK293 cell expression system and enzymatically biotinylated using Avitag™ technology. PCSK9 is autocleaved to the ~14 kDa prodomain (a.a. 31-152) and the ~60 kDa mature form (a.a. 153-692), which run at higher MW by SDS-PAGE.
询价背景介绍 The low density lipoprotein receptor (LDLR) gene family consists of cell surface proteins involved in receptor-mediated endocytosis of specific ligands. Low density lipoprotein (LDL) is normally bound at the cell membrane and taken into the cell ending up in lysosomes where the protein is degraded and the cholesterol is made available for repression of microsomal enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the rate-limiting step in cholesterol synthesis. At the same time, a reciprocal stimulation of cholesterol ester synthesis takes place. Mutations in this gene cause the autosomal dominant disorder, familial hypercholesterolemia. In case of HIV-1 infection, it functions as a receptor for extracellular Tat in neurons, mediating its internalization in uninfected cells. PCSK9 binds to the epidermal growth factor-like repeat A (EGF-A) domain of LDLR, inducing LDLR degradation. 产品介绍 Human low density lipoprotein receptor (LDLR), also known as FH, FHC, and LDLCQ2, GenBank Accession No. NM_000527, a.a. 22-788(end), with C-terminal FLAG and Avi tags, MW=87.7 kDa, expressed in an HEK293 cell expression system and enzymatically biotinylated using Avitag™ technology.
询价背景介绍 The low density lipoprotein receptor (LDLR) gene family consists of cell surface proteins involved in receptor-mediated endocytosis of specific ligands. Low density lipoprotein (LDL) is normally bound at the cell membrane and taken into the cell ending up in lysosomes where the protein is degraded and the cholesterol is made available for repression of microsomal enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the rate-limiting step in cholesterol synthesis. At the same time, a reciprocal stimulation of cholesterol ester synthesis takes place. Mutations in this gene cause the autosomal dominant disorder, familial hypercholesterolemia. In case of HIV-1 infection, it functions as a receptor for extracellular Tat in neurons, mediating its internalization in uninfected cells. PCSK9 binds to the epidermal growth factor-like repeat A (EGF-A) domain of LDLR, inducing LDLR degradation. 产品介绍 Human low density lipoprotein receptor (LDLR), also known as FH, FHC, and LDLCQ2, GenBank Accession No. NM_000527, a.a. 22-788(end), with C-terminal FLAG and Avi tags, MW=87.7 kDa, expressed in an HEK293 cell expression system and enzymatically biotinylated using Avitag™ technology.
询价背景介绍 PCSK9 is a crucial player in the regulation of plasma cholesterol homeostasis. It binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways. 产品介绍 Human proprotein convertase subtilisin/kexin type 9 (PCSK9), also known as FH3, HCHOLA3, and PC9, GenBank Accession No. NM_174936, a.a. 31-692(end), with C-terminal His-tag, MW=71.8 kDa (calculated), expressed in an HEK293 cell expression system.
询价背景介绍 PCSK9 is a crucial player in the regulation of plasma cholesterol homeostasis. It binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways. 产品介绍 Human proprotein convertase subtilisin/kexin type 9 (PCSK9), also known as FH3, HCHOLA3, and PC9, GenBank Accession No. NM_174936, a.a. 31-692(end), with C-terminal His-tag, MW=71.8 kDa (calculated), expressed in an HEK293 cell expression system.
询价产品介绍 Human IDO2, also known as Indoleamine 2,3-dioxygenase 2, GenBank Accession No. NM_194294, a.a. 15-420(end) with an N-terminal His-tag, expressed in the presence of hemin in an E. coli cell expression system. MW = 46 kDa.
询价产品介绍 Human CD73, also known as 5'- nucleotidase and Ecto-5'-nucleotidase, GenBank Accession No. NM_002526, a.a. 27-547 with C-terminal His-tag, expressed in a HEK293 cell expression system. MW = 58.6 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.
询价产品介绍 Human CD73, also known as 5'- nucleotidase and Ecto-5'-nucleotidase, GenBank Accession No. NM_002526, a.a. 27-547 with C-terminal His-tag, expressed in a HEK293 cell expression system. MW = 58.6 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.
询价产品介绍 Human Programmed Cell Death 1 Ligand 1 (PD-L1), also known as CD274 and B7 homolog 1 (B7-H1), PDCD1 ligand 1, programmed death ligand 1, PDCD1L1, GenBank Accession No. NM_014143, a.a. 19-239, with a C-terminal FLAG-tag, expressed in a HEK293 cell expression system. MW = 26 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.
询价
